NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $1.14 +0.05 (+4.59%) (As of 10/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Assertio Stock (NASDAQ:ASRT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Assertio alerts:Sign Up Key Stats Today's Range$1.09▼$1.1450-Day Range$1.07▼$1.4652-Week Range$0.73▼$2.60Volume427,049 shsAverage Volume967,758 shsMarket Capitalization$108.44 millionP/E RatioN/ADividend YieldN/APrice Target$3.44Consensus RatingBuy Company OverviewAssertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More… “A very dark day is coming to America” (Ad)Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.Click here to see his official warning. Assertio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks33rd Percentile Overall ScoreASRT MarketRank™: Assertio scored higher than 33% of companies evaluated by MarketBeat, and ranked 808th out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has only been the subject of 1 research reports in the past 90 days.Read more about Assertio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.17) to $0.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.55% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Assertio has recently increased by 0.48%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.55% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 5.8.Change versus previous monthShort interest in Assertio has recently increased by 0.48%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Assertio this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for ASRT on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address ASRT Stock News HeadlinesAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)October 4 at 4:05 PM | globenewswire.comCannaPharmaRX (OTCMKTS:CPMD) & Assertio (NASDAQ:ASRT) Financial ReviewSeptember 30, 2024 | americanbankingnews.comAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released my latest prediction and believe it or not, I’m advising NOT pour all your money into Nvidia right nowOctober 5, 2024 | Brownstone Research (Ad)Assertio Holdings: Management Change Could Improve Comeback ChancesSeptember 12, 2024 | seekingalpha.comAssertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024September 3, 2024 | globenewswire.comAssertio Therapeutics: Strong Buy Rating on Robust Portfolio and Strategic GrowthAugust 21, 2024 | markets.businessinsider.comAssertio Holdings, Inc. (NASDAQ:ASRT) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | insidermonkey.comBuy Rating Affirmed for Assertio Therapeutics on Strong Financials and Market PositionAugust 9, 2024 | markets.businessinsider.comSee More Headlines ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $1.07 at the beginning of the year. Since then, ASRT shares have increased by 6.5% and is now trading at $1.14. View the best growth stocks for 2024 here. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.02. The firm had revenue of $31.13 million for the quarter, compared to the consensus estimate of $30.37 million. Assertio had a positive trailing twelve-month return on equity of 4.88% and a negative net margin of 261.08%. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN) and Company Calendar Last Earnings8/07/2024Today10/05/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$3.44 High Stock Price Target$4.00 Low Stock Price Target$2.75 Potential Upside/Downside+201.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-331,940,000.00 Net Margins-261.08% Pretax Margin-203.27% Return on Equity4.88% Return on Assets2.37% Debt Debt-to-Equity Ratio0.29 Current Ratio1.93 Quick Ratio1.51 Sales & Book Value Annual Sales$132.19 million Price / Sales0.82 Cash Flow$0.68 per share Price / Cash Flow1.68 Book Value$1.46 per share Price / Book0.78Miscellaneous Outstanding Shares95,125,000Free Float92,081,000Market Cap$108.44 million OptionableOptionable Beta0.79 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:ASRT) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredAI Expert Reveals New PickEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.